Avantor, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Oct 29, 2021 and accepted by EDGAR at Oct 29, 2021, 08:57 ET.
Management's discussion and analysis
As filed, 27,898 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to historical financial information, this discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our results may differ materially from those contained in or implied by any forward-looking statements. You should carefully read “Cautionary factors regarding forward-looking statements” for additional information.
Basis of presentation
This discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes. Pursuant to SEC rules for reports covering interim periods, we have prepared this discussion and analysis to enable you to assess material changes in our financial condition and results of operations since December 31, 2020, the date of our Annual Report. Therefore, we encourage you to read this discussion and analysis in conjunction with the Annual Report.
Overview
We are a leading global provider of mission critical products and services to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries. We have global operations and an extensive product portfolio. We strive to enable customer success through innovation, cGMP manufacturing and comprehensive service offerings. The depth and breadth of our portfolio provides our customers a comprehensive range of products and services and allows us to create customized and integrated solutions for our customers.
During the three months ended September 30, 2021, we recorded net sales of $1,834.3 million, net income of $156.8 million and Adjusted EBITDA of $359.2 million. Net sales increased by 14.3%, which included 10.2% organic growth compared to the same period in 2020. See “Reconciliations of non-GAAP measures” for a reconciliation of net income to Adjusted EBITDA and “Results of operations” for a reconciliation of net sales growth to organic net sales growth.
Factors and current trends affecting our business and results of operations
The following updates the factors and current trends disclosed in the Annual Report. These updates could affect our performance and financial condition in future periods.
Our results are impacted by acquisitions
We completed the acquisitions of Ritter GmbH and Rim Bio in the second quarter of 2021, the results of which are included in the “Results of operations” section below. Additionally, we entered into a definitive agreement to acquire Masterflex on September 7, 2021, which we expect to close on or about November 1, 2021. Details of these transactions can be found in footnote 1 to our financial statements.
Our results continue to be impacted by the ongoing global coronavirus outbreak
The results for each of our three regions continue to be impacted by the COVID-19 pandemic for the three and nine months ended September 30, 2021, as described further in the “Results of operations” section below. COVID-19 has also affected the ability of certain suppliers and vendors to provide products and services to certain of our businesses. While we have not experienced significant or widespread disruption to our supply chain, we have seen increased supply constraints that could have a material impact on our operations.
For a discussion of the impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we experienced through December 31, 2020, see “Part II—Item 7—Management's discussion and analysis of financial condition and results of operations” in the
Annual Report. For additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions to the Company, see “The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.” included in “Part I—Item 1A—Risk factors” in the Annual Report.
Key indicators of performance and financial condition
To evaluate our performance, we monitor a number of key indicators including certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.
The key indicators that we monitor are as follows:
- Net sales, gross margin, operating income and net income or loss. These measures are discussed in the section entitled “Results of operations;”
- Organic net sales growth, which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth eliminates from our reported net sales the impacts of earnings from any acquired or disposed businesses and changes in foreign currency exchange rates. The acquisitions of Ritter GmbH and RIM Bio did not materially impact the results of our operations for the three and nine months ended September 30, 2021. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations;”
- Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is used by investors to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as a way to analyze the underlying trends in our core business consistently across the periods presented. This measurement is used by our management for the same reason. A reconciliation of net income or loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA is included in the section entitled “Reconciliations of non-GAAP measures;”
- Cash flows from operating activities, which we discuss in the section entitled “Liquidity and capital resources—historical cash flows;”
- Free cash flow, which is equal to our cash flow from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. We have amended our definition of free cash flow to exclude acquisition-related costs as they may be significant, individually or in aggregate, and may make it more difficult for investors to understand the free cash flows associated with the normal operations of our business. We believe that this measurement is useful to investors as it
provides a view on the Company’s ability to generate cash for use in financing or investment activities. This measurement is used by management for the same reason.
Results of operations
We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.
Executive summary
(dollars in millions)
| 2021 | Three months ended September 30, 2020 | Change | |
|---|---|---|---|
| Net sales | $1,834.3 | $1,605.0 | $229.3 |
| Gross margin | 33.6% | 31.6% | 200 bps |
| Operating income | $237.2 | $177.2 | $60.0 |
| Net income | 156.8 | (42.2) | 199.0 |
| Adjusted EBITDA | 359.2 | 285.6 | 73.6 |
| Adjusted EBITDA margin | 19.6% | 17.8% | 180 bps |
Third quarter revenue growth reflects strong growth in the biopharma end market, along with modest growth in the healthcare and advanced technologies & applied materials end markets. We continue to generate high single-digit demand in our core business, augmented by our COVID-19 related sales of PPE and solutions to support diagnostic testing and vaccine production. Double-digit growth of our proprietary materials and consumables product group, commercial excellence and productivity contributed to gross margin and Adjusted EBITDA margin expansion.
Net sales
Three months ended
(in millions)
| 2021 | Three months ended September 30, Net sales growth 2020 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth M&A Impact | Organic net sales growth | ||
|---|---|---|---|---|---|---|
| Americas | $1,045.0 | $950.5 | $94.5 | $3.8 | $4.2 | $86.5 |
| Europe | 674.7 | 562.1 | 112.6 | 9.1 | 41.9 | 61.6 |
| AMEA | 114.6 | 92.4 | 22.2 | 2.4 | 4.7 | 15.1 |
| Total | $1,834.3 | $1,605.0 | $229.3 | $15.3 | $50.8 | $163.2 |
Net sales increased $229.3 million or 14.3%, which included $15.3 million or 0.9% of favorable foreign currency impact and $50.8M or 3.2% of M&A impact. Organic growth in net sales was $163.2 million or 10.2% and was primarily due to strong growth in our core business and a modest contribution from COVID-19 related sales.
In the Americas, net sales increased $94.5 million or 10.0%, which included $3.8 million or 0.4% of favorable foreign currency impact and $4.2 million or 0.5% of M&A impact. Organic growth in net sales was $86.5 million or 9.1%. Additional information by end market is as follows:
- Biopharma — Sales grew double-digits driven by continued strong demand in biopharma production as well as sequential improvement of demand in research and development.
- Healthcare — Sales declined low single-digits primarily driven by a reduction of COVID-19 related diagnostic testing revenue. This was partially offset by double-digit growth of our biomaterials platform as demand for elective surgical procedures continues to strengthen.
- Education and government — Sales declined low single-digits primarily due to a reduction of Government purchases of COVID-19 related consumables. This was partially offset from a continued recovery in education demand from academic labs that had been closed due to COVID-19.
- Advanced technologies & applied materials — Sales increased low single-digits driven by sales of proprietary materials and consumables into production platforms such as semiconductors and aerospace and defense and continued improvement in industrial demand.
In Europe, net sales increased $112.6 million or 20.0%, which included $9.1 million or 1.6% of favorable foreign currency impact and $41.9 million or 7.5% of M&A impact. Organic growth in net sales was $61.6 million or 10.9%. Additional information by end market is as follows:
- Biopharma — Sales grew double-digits driven by continued strong demand in biopharma production for process ingredients, excipients and single-use solutions.
- Healthcare — Sales grew double-digits due primarily to increased demand for our proprietary silicone offerings driven by recovery in elective surgical procedures and sales of COVID-19 testing content.
- Education & government — Sales declined low single-digits primarily due to a reduction of government purchases of COVID-19 related consumables.
- Advanced technologies & applied materials — Sales grew double-digits driven by sales of our laboratory materials, consumables and equipment and instrumentation offering.
In AMEA, net sales increased $22.2 million or 24.1%, which included $2.4 million or 2.6% of favorable foreign currency impact and $4.7 million or 5.1% of M&A impact. Organic growth in net sales was $15.1 million or 16.4%. Additional information by end market is as follows:
- Biopharma — Sales grew high-single digits driven by strong demand for our proprietary offering of process ingredients, chromatography resins, excipients, and single use solutions.
- Advanced technologies & applied materials — Sales grew double-digits primarily driven by strong demand for our proprietary offerings into the semiconductor industry.
Nine months ended
(in millions)
| 2021 | Nine months ended September 30, Net sales growth 2020 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth M&A Impact | Organic net sales growth | ||
|---|---|---|---|---|---|---|
| Americas | $3,149.9 | $2,707.1 | $442.8 | $18.6 | $4.2 | $420.0 |
| Europe | 1,991.1 | 1,627.1 | 364.0 | 119.1 | 41.9 | 203.0 |
| AMEA | 337.5 | 268.5 | 69.0 | 12.3 | 4.7 | 52.0 |
| Total | $5,478.5 | $4,602.7 | $875.8 | $150.0 | $50.8 | $675.0 |
Net sales increased $875.8 million or 19.0%, which included $150.0 million or 3.3% of favorable foreign currency impact and $50.8 million or 1.1% of M&A impact. Organic growth in net sales was $675.0 million or 14.6% and was due to growth in both our core business as well as COVID-19 related sales.
In the Americas, net sales increased $442.8 million or 16.4%, which included $18.6 million or 0.7% of favorable foreign currency impact and $4.2 million or 0.2% of M&A impact. Organic growth in net sales was $420.0 million or 15.5% for reasons similar to the three month period. Additionally, year-to-date revenue benefited from tailwinds associated with COVID-19 related diagnostic testing revenue in the first six months of 2021.
In Europe, net sales increased $364.0 million or 22.4%, which included $119.1 million or 7.3% of favorable foreign currency impact and $41.9 million or 2.6% of M&A impact. Organic growth in net sales was $203.0 million or 12.5% for reasons similar to the three month period.
In AMEA, net sales increased $69.0 million or 25.7%, which included $12.3 million or 4.6% of favorable foreign currency impact and $4.7 million or 1.7% of M&A impact. Organic growth in net sales was $52.0 million or 19.4% for reasons similar to the three month period.
Gross margin
| 2021 | Three months ended September 30, 2020 | 2021 | Change 2020 | Nine months ended September 30, | Change | |
|---|---|---|---|---|---|---|
| Gross margin | 33.6% | 31.6% | 200 bps | 33.9% | 32.6% | 130 bps |
Three and nine months ended
Gross margin for the three and nine months ended September 30, 2021 increased 200 basis points and 130 basis points, respectively, resulting primarily from commercial excellence, productivity and favorable product mix due to strong sales of our proprietary product offerings.
Operating income
(in millions)
| 2021 | Three months ended September 30, 2020 | 2021 | Change 2020 | Nine months ended September 30, | Change | |
|---|---|---|---|---|---|---|
| Gross profit | $615.9 | $506.4 | $109.5 | $1,855.2 | $1,498.9 | $356.3 |
| Operating expenses | 378.7 | 329.2 | 49.5 | 1,097.0 | 996.7 | 100.3 |
| Operating income | $237.2 | $177.2 | $60.0 | $758.2 | $502.2 | $256.0 |
Three and nine months ended
Gross profit for the three and nine months ended September 30, 2021 increased $109.5 million and $356.3 million, respectively, due to the reasons described above. The increase in operating expenses primarily relates to acquisition-related expenses, increased incentive compensation expense due to our strong performance in the first nine months of 2021 and unfavorable foreign exchange impacts.
Net income or loss
(in millions)
| 2021 | Three months ended September 30, 2020 | 2021 | Change 2020 | Nine months ended September 30, | Change | |
|---|---|---|---|---|---|---|
| Operating income | $237.2 | $177.2 | $60.0 | $758.2 | $502.2 | $256.0 |
| Interest expense | (54.1) | (65.2) | 11.1 | (156.6) | (251.8) | 95.2 |
| Loss on extinguishment of debt | — | (226.4) | 226.4 | (8.4) | (226.4) | 218.0 |
| Other income, net | 3.4 | 6.6 | (3.2) | 19.8 | 11.6 | 8.2 |
| Income tax (expense) benefit | (29.7) | 65.6 | (95.3) | (134.4) | 29.4 | (163.8) |
| Net income (loss) | $156.8 | $(42.2) | $199.0 | $478.6 | $65.0 | $413.6 |
Three and nine months ended
Net income for the three and nine months ended September 30, 2021 increased by $199.0 million and $413.6 million, respectively, primarily driven by the operating income growth detailed above, lower interest expense from the repricings and refinancings of our debt for more favorable interest rates in 2020 and lower net debt driven by our strong free cash flows. These refinancings also resulted in a loss on extinguishment of debt in 2020. The growth in operating income and reduction in interest expense was partially offset by higher income tax expense as a result of our higher pretax income and the absence of an income tax benefit related to the release of valuation allowances in the third quarter of 2020.
Adjusted EBITDA and Adjusted EBITDA margin
For a reconciliation of Adjusted EBITDA to Net income or loss, the most directly comparable measure under GAAP, see “Reconciliations of non-GAAP financial measures.”
(in millions)
| 2021 Adjusted EBITDA: | Three months ended September 30, 2020 | 2021 | Change 2020 | Nine months ended September 30, | Change | |
|---|---|---|---|---|---|---|
| Americas | $236.3 | $203.6 | $32.7 | $740.0 | $591.0 | $149.0 |
| Europe | 135.5 | 98.4 | 37.1 | 390.4 | 278.4 | 112.0 |
| AMEA | 29.5 | 20.9 | 8.6 | 80.5 | 56.8 | 23.7 |
| Corporate | (42.1) | (37.3) | (4.8) | (122.0) | (104.5) | (17.5) |
| Total | $359.2 | $285.6 | $73.6 | $1,088.9 | $821.7 | $267.2 |
| Adjusted EBITDA margin | 19.6% | 17.8% | 1.8% | 19.9% | 17.9% | 2.0% |
Three months ended
Adjusted EBITDA increased $73.6 million or 25.8%, which included a favorable foreign currency translation impact of $2.7 million or 0.9% and $15.5 million or 5.4% M&A impact.
In the Americas, Adjusted EBITDA grew $32.7 million or 16.1%, or 14.9% when adjusted for favorable foreign currency translation impact and M&A. Gross margin expansion from commercial excellence, favorable volume, strong mix from proprietary products and reduced inventory charges was partially offset by increased incentive compensation expense and inflationary pressures.
In Europe, Adjusted EBITDA grew $37.1 million or 37.8%, or 24.3% when adjusted for favorable foreign currency translation impact and M&A, due to gross margin expansion from favorable volume and commercial excellence and strong mix from proprietary products partially offset by increased incentive compensation expense, inflationary pressures and operational foreign exchange impacts.
In AMEA, Adjusted EBITDA grew $8.6 million or 41.1%, or 28.7% when adjusted for favorable foreign currency translation impact and M&A. In addition to the favorable sales volume we experienced a strong mix of proprietary products. This was partially offset by increased incentive compensation expense, inflationary pressures and operational foreign exchange impacts.
In Corporate, Adjusted EBITDA declined $4.8 million or 12.8% reflecting higher incentive compensation expense, inflationary pressures and increased stock-based compensation expense.
Nine months ended
Adjusted EBITDA increased $267.2 million or 32.5%, which included a favorable foreign currency translation impact of $26.9 million or 3.2% and $15.5M or 1.9% M&A impact.
In the Americas, Adjusted EBITDA grew $149.0 million or 25.2%, or 24.3% when adjusted for favorable foreign currency translation impact and M&A for reasons similar to the three month period.
In Europe, Adjusted EBITDA grew $112.0 million or 40.3%, or 28.7% when adjusted for favorable foreign currency translation impact and M&A for reasons similar to the three month period.
In AMEA, Adjusted EBITDA grew $23.7 million or 41.7%, or 32.7% when adjusted for favorable foreign currency translation and M&A for reasons similar to the three month period.
In Corporate, Adjusted EBITDA declined $17.5 million or 16.7% for reasons similar to the three month period.
Reconciliations of non-GAAP financial measures
The following table presents the reconciliation of net income or loss to Adjusted EBITDA:
(in millions)
| 2021 | Three months ended September 30, 2020 | 2021 | Nine months ended September 30, 2020 | |
|---|---|---|---|---|
| Net income (loss) | $156.8 | $(42.2) | $478.6 | $65.0 |
| Interest expense | 54.1 | 65.2 | 156.6 | 251.8 |
| Income tax expense (benefit) | 29.7 | (65.6) | 134.4 | (29.4) |
| Depreciation and amortization | 100.0 | 99.1 | 275.1 | 293.4 |
| Loss on extinguishment of debt | — | 226.4 | 8.4 | 226.4 |
| Net foreign currency (gain) loss from financing activities | (0.8) | (4.1) | 1.2 | (4.3) |
| Other stock-based compensation expense | 1.6 | 0.6 | 2.9 | 0.6 |
| Acquisition-related expenses1 | 3.2 | — | 27.8 | — |
| Integration-related expenses2 | 7.9 | 3.9 | 8.4 | 11.5 |
| Purchase accounting adjustments3 | 6.3 | — | 6.3 | — |
| Restructuring and severance charges4 | 0.4 | 2.3 | 2.2 | 6.7 |
| Receipt of disgorgement penalty5 | — | — | (13.0) | — |
| Adjusted EBITDA | $359.2 | $285.6 | $1,088.9 | $821.7 |
1. Represents legal, accounting, investment banking and consulting fees incurred related to completed and pending acquisitions. Generally, these expenses are incurred prior to and at the closing of acquisitions.
2. Represents non-recurring direct costs incurred with third-parties to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
3. Represents the amortization of the purchase accounting adjustment we made to reflect Ritter’s acquired inventory at fair value upon acquisition, as shown in note 3 to our unaudited interim financial statements.
4. Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.
5. As described in note 13 to our unaudited interim financial statements.
Liquidity and capital resources
We fund short-term cash requirements primarily from operating cash flows. Most of our long-term financing is from indebtedness. For the three and nine month periods ended September 30, 2021, we generated $261.9 million and $652.6 million of cash from operating activities, respectively, ended the quarter with $1,426.1 million of cash and cash equivalents and our availability under credit facilities was $804.2 million. Required debt repayments due in the next twelve months other than required term loan payments are $30.1 million. Included in our cash and cash equivalents balance at September 30, 2021 is $967.0 million of net proceeds that we raised through a secondary offering of our common stock on September 15, 2021, which will be used to partially finance the acquisition of Masterflex.
Liquidity
The following table presents our primary sources of liquidity:
(in millions)
| September 30, 2021 Receivables facility Revolving credit facility Total Unused availability under credit facilities: | |
|---|---|
| Capacity $300.0 $515.0 | $815.0 |
| Undrawn letters of credit outstanding (9.2) (1.6) | (10.8) |
| Outstanding borrowings — — | — |
| Unused availability $290.8 $513.4 | $804.2 |
| Cash and cash equivalents | 1,426.1 |
| Total liquidity | $2,230.3 |
Some of our credit line availability depends upon maintaining a sufficient borrowing base of eligible accounts receivable. We believe that we have sufficient capital resources to meet our liquidity needs.
Our debt agreements include representations and covenants that we consider usual and customary, and our receivables facility and senior secured credit facilities include a financial covenant that becomes applicable for periods in which we have drawn more than 35% of our revolving credit facility under the senior secured credit facilities. In this circumstance, we are not permitted to have combined borrowings on our senior secured credit facilities and secured notes in excess of a pro forma net leverage ratio, as defined. As we had not drawn more than 35% of our revolving credit facility in this period, this covenant was not applicable at September 30, 2021.
At September 30, 2021, $236.6 million or 16.6% of our $1,426.1 million in cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply.
Historical cash flows
The following table presents a summary of cash provided by (used in) various activities:
(in millions)
| 2021 Operating activities: | Nine months ended September 30, 2020 | Change | |
|---|---|---|---|
| Net income | $478.6 | $65.0 | 413.6 |
| Non-cash items | 347.1 | 533.2 | (186.1) |
| Working capital changes1,2 | (175.1) | (31.1) | (144.0) |
| All other1 | 2.0 | 56.7 | (54.7) |
| Total | $652.6 | $623.8 | $28.8 |
| Investing activities | $(1,238.2) | $(40.3) | $(1,197.9) |
| Cash paid for acquisitions, net of cash acquired | (1,168.9) | — | (1,168.9) |
| Capital expenditures | (71.1) | (41.4) | (29.7) |
| Financing activities | 1,758.2 | (402.5) | 2,160.7 |
1. The amounts previously reported as “working capital changes” and “all other” for the nine months ended September 30, 2020 have been revised in the above table to give effect to the correction of an immaterial classification error disclosed in note 1 to our unaudited interim financial statements.
2. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.
Cash flows from operating activities provided $28.8 million more cash in 2021 primarily due to significantly higher net income offset by increased working capital requirements and larger payouts under our incentive compensation plan due to the strong performance of our business.
Investing activities used $1,197.9 million more cash in 2021, reflecting cash paid to acquire Ritter GmbH and RIM Bio, as well as increased capital spending.
Financing activities provided $2,160.7 million more cash in 2021 primarily due to our secondary equity offering, the issuance of new tranches of Euro term loans to finance the acquisition of Ritter GmbH, and higher proceeds from employees exercising stock options.
Free cash flow
(in millions)
| 2021 | Nine months ended September 30, 2020 | Change | |
|---|---|---|---|
| Net cash provided by operating activities | $652.6 | $623.8 | $28.8 |
| Acquisition-related expenses paid | 24.6 | — | 24.6 |
| Capital expenditures | (71.1) | (41.4) | (29.7) |
| Free cash flow | $606.1 | $582.4 | $23.7 |
Free cash flow was $23.7 million higher in 2021 due to the changes in cash flows from operating activities noted above, which included the payment of $24.6 million of non-recurring costs related to the acquisitions of Ritter and RIM Bio, offset by an increase in capital spending. Refer to “Reconciliations of non-GAAP financial measures” for disclosure regarding acquisition-related expenses.
Indebtedness
For information about our indebtedness, refer to the section entitled “Liquidity” and note 10 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”
New accounting standards
For information about new accounting standards, see note 2 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”
Controls and procedures
As filed, 1,014 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management’s evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2021, the design and operation of our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
Changes in internal control over financial reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter ended September 30, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 316 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Annual Report.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $1.83bn | us-gaap:Revenues |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $5.48bn | us-gaap:Revenues |
| Cost of revenue | 3 months2021-07-01 to 2021-09-30 | $1.22bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2021-01-01 to 2021-09-30 | $3.62bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-07-01 to 2021-09-30 | $615.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2021-01-01 to 2021-09-30 | $1.86bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2021-07-01 to 2021-09-30 | $378.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2021-01-01 to 2021-09-30 | $1.10bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | $237.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | $758.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $54.1m | us-gaap:InterestExpense |
| Interest expense | 9 months2021-01-01 to 2021-09-30 | $156.6m | us-gaap:InterestExpense |
| Income tax | 3 months2021-07-01 to 2021-09-30 | $29.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | $134.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-07-01 to 2021-09-30 | $156.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | $478.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | $0.24 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | $0.73 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | $0.24 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-09-30 | 598,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-09-30 | 593,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | $652.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $71.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $1.43bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $3.56bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $12.20bn | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $1.32bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $8.09bn | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $5.55bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-09-30 | $37.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-09-30 | $4.10bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001722482-21-000246. Last ingested by Listed: Nov 13, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.